首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症

市場調查報告書

商品編碼

2103142

循環性腫瘤細胞檢測市場：策略性洞察與預測（2026-2035）

Circulating Tumor Cell Testing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年07月09日 | 出版商:

Knowledge Sourcing Intelligence | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

循環性腫瘤細胞檢測市場預計將從 2026 年的 9 億美元成長到 2035 年的 20.1 億美元，複合年成長率為 9.3%。

循環性腫瘤細胞檢測市場正經歷模式轉移。這一市場演變的特點是，人們日益認知到精準腫瘤學越來越依賴能夠反映腫瘤在整個治療過程中不斷演變的生物學特徵的生物標記，而不僅僅是單次組織學表徵。先進的細胞分離技術、分子表徵平台和人工智慧的融合，使得對原發性和轉移性腫瘤釋放到血液中的罕見癌細胞進行更全面的分析成為可能。醫療系統正在將循環性腫瘤細胞檢測整合到精準腫瘤學計畫中，因為重複抽血可以提供連續的切片檢查訊息，而無需多次侵入性活體組織切片。雖然傳統切片檢查對於初始診斷仍然至關重要，但由於手術風險、樣本量有限以及疾病進展過程中的取樣偏差等問題，它們經常面臨挑戰。製藥公司正在將循環性腫瘤細胞分析納入抗癌藥物的研發，因為縱向生物標記監測能夠最佳化臨床試驗設計和患者選擇。隨著市場上對自動化分離平台、多體學整合和人工智慧驅動的細胞分析的大量投資，循環性腫瘤細胞檢測正在成為多種癌症適應症中組織切片檢查的補充診斷方法。

市場促進因素

精準腫瘤學的日益普及是循環性腫瘤細胞細胞學市場的主要驅動力。精準腫瘤學越來越依賴能夠反映腫瘤在治療過程中不斷變化的生物學特徵的生物標記。循環性腫瘤細胞細胞學透過重複切片檢查提供連續的分子訊息，無需多次侵入性活體組織切片，因此其需求正在轉變。在晚期癌症中，組織樣本往往有限，導致人們越來越依賴液態生物檢體技術來監測治療反應和新出現的抗藥性機制。診斷開發公司正在擴展其綜合分子分析能力，以支持多種癌症適應症的個人化治療選擇，從而推動循環性腫瘤細胞細胞學應用的持續成長。臨床上對液態生物檢體技術的日益青睞進一步加速了市場成長。液態生物檢體技術為疾病監測提供了一種微創替代方案，同時減輕了患者的檢測負擔。隨著治療決策越來越依賴縱向生物標記評估而非孤立的診斷觀察，醫療機構正在引入連續血液檢測。傳統組織切片檢查由於其複雜性和相關風險仍存在局限性，這促使人們更廣泛地採用輔助診斷方法。伴隨診斷的快速發展推動了對檢驗的檢測解決方案的需求。在標靶治療中，準確的生物標記識別對於最大限度地提高治療效果至關重要。製藥公司正在將循環性腫瘤細胞分析納入其臨床開發項目，因為基於生物標記的患者選擇能夠提高臨床試驗的效率並改善治療評估。診斷設備製造商正在加強與腫瘤藥物研發者的合作，以建立與精準治療策略相符的、經臨床檢驗的生物標記平台。細胞分離和分子表徵技術的進步正在提升分析能力。成功分析循環性腫瘤細胞需要從周邊血液中高效回收稀有癌細胞。檢查室需要高度自動化的平台，該平台應具備可重複的分析效能和擴充性的工作流程。各公司正在建構整合免疫磁分離、微流體技術、數位影像和基因組分析的診斷工作流程，以提高分析準確性。

市場限制因素

由於臨床標準化不足，檢查室採用的濃縮方法、檢測技術和報告標準各不相同，降低了檢測平台之間的可比較性。缺乏標準化的操作規程為確保結果解讀的一致性和臨床可靠性帶來了挑戰。高昂的實施和營運成本限制了檢測技術的常規應用，尤其是在醫療系統中，必須先證明其臨床效用才能擴大保險覆蓋範圍。對專用設備和專業技術所需的大量投資是小規模檢查室和機構的一大障礙。循環性腫瘤細胞濃度極低，為分析帶來了挑戰，因為可靠的檢測需要高靈敏度的濃縮技術和標準化的檢查室專業技術。標靶細胞在數十億血球中極為稀少，因此需要先進的分離和檢測技術。複雜且因地區而異的法規給尋求將新型檢測方案商業化的診斷設備製造商帶來了合規負擔。不斷變化的監管環境要求持續調整，導致營運成本增加，新產品上市時間延長。

依產品
- 試劑盒和試劑
- 採血管和自動化分離平台
透過生物標記
- 上皮細胞黏附分子（EpCAM）
- 細胞角質蛋白
- 腫瘤相關抗原
- 其他生物標記
依樣本類型
- 全血
- 骨髓
- 其他生物檢體
透過使用
- 癌症早期發現
- 治療反應和監測
- 腫瘤分子譜分析
- 其他
按癌症類型
- 乳癌
- 攝護腺癌
- 結腸癌
- 肺癌
- 其他固體癌
最終用戶
- 醫院
- 癌症中心
- 臨床診斷檢測實驗室
- 其他

第10章全球循環性腫瘤細胞檢測市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球循環性腫瘤細胞檢測市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
中國
日本
韓國
印度
澳洲
巴西
墨西哥
沙烏地阿拉伯
阿拉伯聯合大公國
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Menarini Group
Bio-Techne Corporation
QIAGEN NV
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc.
Miltenyi Biotec BV & Co. KG
Epic Sciences Inc.
ANGLE plc
Precision Medicine Group
Biolidics Limited

第14章：全球循環性腫瘤細胞檢測市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009033

The Circulating Tumor Cell Testing Market is expected to grow at a CAGR of 9.3% from a market value of USD 0.90 billion in 2026 to USD 2.01 billion in 2035.

The circulating tumor cell testing market is undergoing significant transformation driven by the paradigm shift toward minimally invasive oncology diagnostics and dynamic biomarker assessment. The market's evolution is characterized by the growing recognition that precision oncology increasingly depends on biomarkers reflecting evolving tumor biology throughout treatment rather than single-point tissue characterization. The convergence of advanced cell isolation technologies, molecular characterization platforms, and artificial intelligence is enabling more comprehensive analysis of rare tumor cells released from primary or metastatic tumors into the bloodstream. Healthcare systems are integrating circulating tumor cell testing into precision oncology programs because repeated blood sampling provides continuous molecular information without requiring multiple invasive biopsies. Conventional biopsies remain essential for initial diagnosis but often present procedural risks, limited accessibility, and sampling bias during disease progression. Pharmaceutical companies are incorporating circulating tumor cell analysis into oncology drug development because longitudinal biomarker monitoring strengthens clinical trial design and patient selection. The market is witnessing significant investment in automated isolation platforms, multi-omics integration, and AI-enabled cellular analysis, positioning circulating tumor cell testing as a complementary diagnostic approach to tissue biopsy across multiple cancer indications.

Market Drivers

The rising adoption of precision oncology represents the primary driver for the circulating tumor cell testing market. Precision oncology increasingly depends on biomarkers that reflect evolving tumor biology throughout treatment. Demand is shifting toward circulating tumor cell testing because repeated blood sampling provides continuous molecular information without requiring multiple invasive biopsies. Tissue availability frequently becomes limited during advanced disease, which increases dependence on liquid biopsy technologies capable of monitoring therapeutic response and emerging resistance mechanisms. Diagnostic developers are expanding integrated molecular analysis capabilities that support personalized treatment selection across multiple cancer indications, resulting in sustained growth in circulating tumor cell testing utilization. The increasing clinical preference for liquid biopsy technologies is further accelerating market expansion. Liquid biopsy technologies provide minimally invasive alternatives for disease monitoring while reducing procedural burden for patients. Healthcare providers are incorporating serial blood-based assessments because treatment decisions increasingly depend on longitudinal biomarker evaluation rather than isolated diagnostic findings. Conventional tissue biopsies remain constrained by accessibility and procedural risks, which encourage broader adoption of complementary diagnostic approaches. The expansion of companion diagnostic development is driving demand for validated testing solutions. Targeted therapies require accurate biomarker identification to maximize therapeutic benefit. Pharmaceutical companies are incorporating circulating tumor cell analysis into clinical development programs because biomarker-driven patient selection improves trial efficiency and therapeutic evaluation. Diagnostic companies are strengthening partnerships with oncology drug developers to establish clinically validated biomarker platforms that align with precision treatment strategies. Technological advancements in cell isolation and molecular characterization are improving analytical performance. Successful circulating tumor cell analysis depends on efficient recovery of rare tumor cells from peripheral blood. Demand is increasing for highly automated platforms because laboratories require reproducible analytical performance and scalable workflows. Companies are integrating immunomagnetic separation, microfluidic technologies, digital imaging, and genomic analysis into unified diagnostic workflows that improve analytical accuracy.

Market Restraints

Limited clinical standardization reduces comparability between testing platforms because enrichment methods, detection technologies, and reporting criteria vary across laboratories. The lack of standardized protocols creates challenges for consistent interpretation and clinical confidence. High technology acquisition and operational costs restrict routine implementation, particularly within healthcare systems that require demonstrated clinical utility before reimbursement expansion. The significant investment needed for specialized equipment and expertise creates barriers for smaller laboratories and facilities. Extremely low circulating tumor cell concentrations create analytical challenges because reliable detection depends on highly sensitive enrichment technologies and standardized laboratory expertise. The rarity of target cells among billions of hematologic cells requires sophisticated isolation and detection methods. Regulatory complexities across different jurisdictions create compliance burdens for diagnostic manufacturers seeking to commercialize new testing solutions. The evolving regulatory landscape requires continuous adaptation, increasing operational costs and time-to-market for new products.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated analytical workflows. Demand is increasing for highly automated platforms because laboratories require reproducible analytical performance and scalable workflows. Manufacturers are developing highly selective enrichment technologies, automated isolation platforms, and advanced imaging systems that improve cell recovery while preserving cellular integrity for downstream molecular analyses. Microfluidic enrichment platforms, label-free isolation technologies, and artificial intelligence-assisted cellular imaging are enabling more efficient rare cell capture and characterization. Single-cell genomic analysis is expanding the molecular information available from circulating tumor cells. The segment analysis reveals that kits and reagents constitute the fundamental consumables required for circulating tumor cell testing because every analytical workflow depends on standardized sample preparation, cell enrichment, labeling, and molecular characterization. Demand is increasing as hospitals, cancer centers, and clinical diagnostic laboratories expand liquid biopsy testing within precision oncology programs. Breast cancer, prostate cancer, colorectal cancer, and lung cancer represent major testing opportunities because these solid tumors frequently release tumor cells into the bloodstream during disease progression. Treatment response and monitoring represent the largest application segment because clinicians require serial assessment of therapeutic effectiveness. Tumor molecular profiling is gaining adoption because molecular characterization of circulating tumor cells provides clinically relevant information regarding metastatic potential and evolving tumor heterogeneity. Hospitals represent a significant end-user segment because multidisciplinary oncology services increasingly require integrated diagnostic capabilities for routine cancer management. Cancer centers and clinical diagnostic laboratories are expanding specialized testing services to support precision oncology programs. The integration of artificial intelligence is becoming increasingly important because manual interpretation of circulating tumor cell morphology limits scalability across high-volume laboratories. AI-assisted image analysis improves consistency while reducing operator variability, supporting standardized reporting across geographically distributed laboratories.

Competitive and Strategic Outlook

The competitive landscape features specialized liquid biopsy companies alongside established molecular diagnostics providers. Menarini Group is recognized for commercializing clinically validated circulating tumor cell technologies, with its portfolio supporting standardized CTC detection and monitoring. Bio-Techne Corporation supports CTC research through its broad portfolio of life science reagents, antibodies, and cell analysis solutions, focusing on enabling high-quality biomarker discovery and translational oncology research. QIAGEN leverages its expertise in molecular diagnostics and sample preparation to complement circulating tumor cell analysis, with genomic workflow solutions enhancing downstream molecular profiling. Bio-Rad Laboratories provides advanced molecular biology and digital PCR technologies that strengthen CTC biomarker analysis. Thermo Fisher Scientific delivers integrated laboratory technologies, sequencing platforms, and flow cytometry solutions that support circulating tumor cell isolation and characterization. Miltenyi Biotec specializes in magnetic cell separation and automated cell processing technologies that facilitate rare cell enrichment. Epic Sciences develops advanced liquid biopsy technologies capable of analyzing circulating tumor cells without enrichment, supporting comprehensive biomarker assessment. ANGLE plc focuses on proprietary microfluidic technology for capturing intact circulating tumor cells from blood samples, supporting molecular characterization and companion diagnostics. Companies are pursuing product portfolio expansion through innovation in microfluidic enrichment platforms, AI-assisted imaging, and multi-omics integration. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include Gene Solutions announcing that SPOT-MAS 10 places Asia-led cancer screening innovation in the global spotlight as a breakthrough multi-cancer screening test using AI and NGS technology. Quest Diagnostics received FDA Breakthrough Device Designation for the company's Haystack MRD test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

The circulating tumor cell testing market is positioned for sustained growth driven by the convergence of precision oncology, technological innovation, and expanding healthcare investment. The transition from simple cell enumeration toward comprehensive molecular characterization represents a fundamental shift in liquid biopsy applications. While challenges related to limited clinical standardization, high costs, and analytical sensitivity persist, strategic investments in technology, clinical validation, and regulatory compliance are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with circulating tumor cell testing evolving into an integral component of comprehensive liquid biopsy strategies supporting early cancer detection, treatment monitoring, and minimal residual disease assessment.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Circulating Tumor Cell Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Cancer Epidemiology and Disease Burden Analysis
3.8 Role of Circulating Tumor Cell Testing in Precision Oncology
3.9 Clinical Utility Across Cancer Types
3.10 Patient Journey Analysis for CTC Testing
3.11 Testing Volume Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Artificial Intelligence Integration in CTC Analysis
6.6 Multi-Omics and Molecular Characterization of Circulating Tumor Cells
6.7 Automation and High-Throughput Testing Platforms
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Circulating Tumor Cell Testing Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by End User

9. Global Circulating Tumor Cell Testing Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Kits & Reagents
- 9.1.2 Blood Collection Tubes & Automated Isolation Platform
9.2 By Biomarker
- 9.2.1 Epithelial Cell Adhesion Molecule (EpCAM)
- 9.2.2 Cytokeratins
- 9.2.3 Tumor-Associated Antigens
- 9.2.4 Other Biomarkers
9.3 By Sample Type
- 9.3.1 Whole Blood
- 9.3.2 Bone Marrow
- 9.3.3 Other Biological Samples
9.4 By Application
- 9.4.1 Early Cancer Detection
- 9.4.2 Treatment Response and Monitoring
- 9.4.3 Tumor Molecular Profiling
- 9.4.4 Others
9.5 By Cancer Type
- 9.5.1 Breast Cancer
- 9.5.2 Prostate Cancer
- 9.5.3 Colorectal Cancer
- 9.5.4 Lung Cancer
- 9.5.5 Other Solid Tumors
9.6 By End User
- 9.6.1 Hospitals
- 9.6.2 Cancer Centers
- 9.6.3 Clinical Diagnostic Laboratories
- 9.6.4 Others

10. Global Circulating Tumor Cell Testing Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Circulating Tumor Cell Testing Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 China
11.10 Japan
11.11 South Korea
11.12 India
11.13 Australia
11.14 Brazil
11.15 Mexico
11.16 Saudi Arabia
11.17 United Arab Emirates
11.18 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Menarini Group
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Bio-Techne Corporation
13.3 QIAGEN N.V.
13.4 Bio-Rad Laboratories, Inc.
13.5 Thermo Fisher Scientific Inc.
13.6 Miltenyi Biotec B.V. & Co. KG
13.7 Epic Sciences Inc.
13.8 ANGLE plc
13.9 Precision Medicine Group
13.10 Biolidics Limited